BiotechTube

V591

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronavirus Disease (COVID-19)

Conditions

Coronavirus Disease (COVID-19)

Trial Timeline

Aug 27, 2020 → Mar 5, 2021

NCT ID
NCT04498247

About V591

V591 is a phase 1/2 stage product being developed by Merck for Coronavirus Disease (COVID-19). The current trial status is terminated. This product is registered under clinical trial identifier NCT04498247. Target conditions include Coronavirus Disease (COVID-19).

What happened to similar drugs?

0 of 12 similar drugs in Coronavirus Disease (COVID-19) were approved

Approved (0) Terminated (2) Active (10)
❌Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
❌EQ001 + EQ001 PlaceboBioconPhase 3
🔄Molnupiravir + PlaceboMerckPhase 3
🔄Efprezimod alfa + PlaceboMerckPhase 3
🔄Molnupiravir + PlaceboMerckPhase 3
🔄Canakinumab + PlaceboNovartisPhase 3
🔄anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04498247Phase 1/2Terminated

Competing Products

20 competing products in Coronavirus Disease (COVID-19)

See all competitors
ProductCompanyStageHype Score
COVID-19 VaccineModernaPreclinical
0
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mgEli LillyPhase 2/3
38
EQ001 + EQ001 PlaceboBioconPhase 3
32
Mesenchymal stem cellRohto PharmaceuticalPhase 1
29
ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04AbbViePhase 1
29
Ibrutinib + PlaceboAbbViePhase 2
35
600 mg AZD7442 IV + 600mg placebo IVAstraZenecaPhase 2
35
EVUSHELDAstraZenecaPre-clinical
26
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])AstraZenecaPhase 2
27
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IVAstraZenecaPhase 1
29
Molnupiravir + PlaceboMerckPhase 3
40
Molnupiravir + PlaceboMerckPhase 2/3
38
V590MerckPhase 1
21
Molnupiravir + PlaceboMerckPhase 2/3
30
Efprezimod alfa + PlaceboMerckPhase 3
40
M5049 + M5049 + PlaceboMerckPhase 2
35
Molnupiravir + PlaceboMerckPhase 3
47
Frespaciguat + PlaceboMerckPhase 1
21
Canakinumab + PlaceboNovartisPhase 3
40